This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Ovid Therapeutics appoints Anna Greka
Business board appointment

Ovid Therapeutics appoints Anna Greka

Analysis based on 7 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The appointment of Anna Greka>>> to the Board of Directors of Ovid Therapeutics is likely to be viewed positively by the market, as her extensive scientific and entrepreneurial experience could accelerate the company's drug development programs. This could lead to increased investor confidence and potentially a positive impact on Ovid Therapeutics' stock price.

biotechnology pharmaceuticals
Event Summary

Ovid Therapeutics Inc. announced the appointment of Anna Greka>>>, a distinguished physician-scientist and biotech entrepreneur, to its Board of Directors, effective June 15, 2026. Anna Greka>>> brings over 25 years of experience in advancing biological discoveries into clinical-stage assets and has founded and advised multiple biotechnology companies, including Goldfinch Bio and a stealth company recently acquired by AstraZeneca. She will chair Ovid Therapeutics' newly formed Science and Technology Committee and serve on the Compensation Committee. This strategic appointment is expected to bolster Ovid Therapeutics' scientific leadership and enhance its efforts in developing therapies for neurological and neuropsychiatric disorders.

Entities Involved
stock
Ovid Therapeutics
Ovid Therapeutics appointed Anna Greka>>> to its Board of Directors, which is expected to enhance its scientific leadership and strategic insight in developing therapies for brain disorders.
Importance 100.0 Sentiment 40.0
per
Anna Greka
Anna Greka>>> was appointed to the Board of Directors of Ovid Therapeutics, where she will contribute her extensive experience in scientific leadership and biotech entrepreneurship. She will also chair the new Science and Technology Committee.
Importance 90.0 Sentiment 50.0
per
Alexander Wang
Alexander Wang>>>, President and CEO of Ovid Therapeutics, commented on the appointment of Anna Greka>>> to the board, highlighting her value to the company.
Importance 20.0 Sentiment 0.0
ngo
Broad Institute
Anna Greka>>> is a Core Institute Member and serves on the Executive Leadership Team at the Broad Institute, showcasing her academic leadership.
Importance 10.0 Sentiment 0.0
priv
Goldfinch Bio
Anna Greka>>> founded Goldfinch Bio, a biotechnology company whose lead asset was later acquired by Bristol Myers Squibb.
Importance 5.0 Sentiment 0.0
ngo
American Society for Clinical Investigation
Anna Greka>>> was elected President of the American Society for Clinical Investigation, recognizing her scientific contributions.
Importance 5.0 Sentiment 0.0
stock
Bristol Myers Squibb
Bristol Myers Squibb acquired the lead asset from Goldfinch Bio, a company founded by Anna Greka>>>.
Importance 5.0 Sentiment 0.0
stock
AstraZeneca
AstraZeneca recently acquired a stealth company based on discoveries made by Anna Greka>>>'s team.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.